Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients

NCT07306702 | Withdrawn Phase 4

• 2 other identifiers: SYCHS6-LOB-PCIA-RCT-2023JUH-CCP-RC-RETRO-01
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This randomized, double-blind, controlled clinical trial evaluates whether adding dexmedetomidine to an oliceridine-based patient-controlled intravenous analgesia (PCIA) regimen can improve postoperative pain control and tolerability after video-assisted thoracoscopic lobectomy in adults with high nicotine dependence (Fagerström score ≥6). A total of 102 participants are allocated 1:1:1 into three groups: (1) oliceridine PCIA alone; (2) oliceridine PCIA plus low-dose dexmedetomidine (0.05 μg/kg/h); or (3) oliceridine PCIA plus standard-dose dexmedetomidine (0.1 μg/kg/h). PCIA solutions are prepared to 100 mL, delivered with a basal rate of 2 mL/h, a 0.5-mL bolus, and a 15-minute lockout; a small loading dose is given near the end of surgery. Tramadol is permitted as rescue analgesia per protocol. The primary objectives are to compare postoperative pain intensity at rest and with movement and overall patient satisfaction within 48-72 hours after surgery. Secondary objectives include sedation level, negative affect (anxiety/depression) scores, comfort and functional recovery scales, effective PCIA presses, rescue analgesic use, and safety outcomes (nausea/vomiting, shivering, bradycardia, hypotension, hypoxemia, and respiratory depression). Outcomes are assessed at approximately 4, 8, 12, 24, and 48 hours after surgery, with a satisfaction survey at 72 hours. The investigators hypothesize that oliceridine PCIA combined with dexmedetomidine-particularly at 0.1 μg/kg/h-will reduce movement-related pain, decrease rescue opioid needs and PCIA presses, improve mood and comfort scores, and maintain acceptable hemodynamic and respiratory safety compared with oliceridine alone.

Conditions

Postoperative Pain Management

Outcome Measures

Primary Outcomes (1)

• Movement-evoked pain intensity (VAS 0-10) within 48 hours after surgery

  Pain during standardized movement (deep breathing/cough or turning in bed) measured on a 10-cm visual analog scale (0=no pain, 10=worst imaginable pain). Trained nurses record scores at each time point. Higher scores indicate worse pain. The primary analysis compares groups on the mean of all movement VAS values collected from 0-48 h postoperatively.

  Within 48 hours after surgery (assessed at 4, 8, 12, 24, and 48 hours after surgery; primary endpoint is the mean VAS across all assessments during the first 48 hours after surgery).

Study Arms (3)

Oliceridine PCIA Alone

ACTIVE COMPARATOR

Postoperative patient-controlled intravenous analgesia (PCIA) using oliceridine only. Reservoir 100 mL; basal 2 mL/h; bolus 0.5 mL; lockout 15 min; \~3 mL loading dose given near the end of surgery. Used for up to 48 h after lobectomy. Tramadol 50-100 mg IV permitted as rescue per protocol. No dexmedetomidine infusion.

Drug: Oliceridine

Oliceridine + Low-Dose Dexmedetomidine

EXPERIMENTAL

Same oliceridine PCIA parameters as Arm 1, plus a continuous IV infusion of dexmedetomidine at 0.05 μg/kg/h (0.05 mcg/kg/h) for up to 48 h postoperatively. Tramadol 50-100 mg IV permitted as rescue per protocol.

Drug: Oliceridine; Drug: Dexmedetomidine

Oliceridine + Standard-Dose Dexmedetomidine

EXPERIMENTAL

Same oliceridine PCIA parameters as Arm 1, plus a continuous IV infusion of dexmedetomidine at 0.10 μg/kg/h (0.1 mcg/kg/h) for up to 48 h postoperatively. Tramadol 50-100 mg IV permitted as rescue per protocol.

Drug: Oliceridine; Drug: Dexmedetomidine

Interventions

Oliceridine DRUG

Patient-controlled intravenous analgesia (PCIA) after VATS lobectomy using oliceridine only. 100-mL reservoir; basal rate 2 mL/h; 0.5-mL bolus; 15-min lockout; \~3-mL loading near end of surgery; used for up to 48 h. Tramadol 50-100 mg IV permitted as rescue per protocol.

Oliceridine + Low-Dose Dexmedetomidine; Oliceridine + Standard-Dose Dexmedetomidine; Oliceridine PCIA Alone

Dexmedetomidine DRUG

Continuous IV infusion as an adjuvant to the oliceridine PCIA per group assignment for up to 48 h: 0.05 μg/kg/h in Arm 2 or 0.10 μg/kg/h in Arm 3. Infusion may be held for HR \<50 bpm or MAP \<65 mmHg per protocol.

Oliceridine + Low-Dose Dexmedetomidine; Oliceridine + Standard-Dose Dexmedetomidine

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• American Society of Anesthesiologists (ASA) physical status II-III
• Male patients aged 65 years or younger
• Undergoing lobectomy for the first time
• High nicotine dependence, confirmed by the Fagerström Test for Nicotine Dependence (FTND) with an FTND score of 6 or higher
• No history of substance abuse and no recent use of analgesic medications (e.g., opioids or non-steroidal anti-inflammatory drugs) prior to surgery
• Able to understand the procedure for patient-controlled intravenous analgesia (PCIA) and able to complete the study assessment scales

You may not qualify if:

• History of mental illness or cognitive disorder; or currently receiving antidepressant treatment and unable to cooperate with examinations and assessments
• Bradycardia (heart rate 50 beats/min or lower) or second- or third-degree atrioventricular block
• Body mass index (BMI) greater than 30 kg/m²
• Use of analgesics, sedatives, beta-blockers, or alpha-2 agonists prior to surgery
• Required reoperation due to serious postoperative complications (e.g., bleeding)
• Severe cardiovascular, cerebrovascular, hepatic, or renal disease, resulting in inability to remove the endotracheal tube after surgery or inability to use the analgesia pump correctly
• Failure to abstain from smoking for at least 2 weeks prior to surgery

Sponsors & Collaborators

• Shenyang Sixth People's Hospital: lead

Study Sites (1)

Shenyang Chest Hospital, Department of Anesthesiology

Shenyang, Liaoning, 110044, China

Location

MeSH Terms

Interventions

((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine; Dexmedetomidine

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: November 21, 2025
• First Posted: December 29, 2025
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): May 30, 2027
• Study Completion (Estimated): May 30, 2027
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)